Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Second monotherapy in childhood absence epilepsy.

Cnaan A, Shinnar S, Arya R, Adamson PC, Clark PO, Dlugos D, Hirtz DG, Masur D, Glauser TA; Childhood Absence Epilepsy Study Group.

Neurology. 2017 Jan 10;88(2):182-190. doi: 10.1212/WNL.0000000000003480. Epub 2016 Dec 16.

PMID:
27986874
2.

Obesity and overweight as CAE comorbidities and differential drug response modifiers.

Arya R, Gillespie CW, Cnaan A, Devarajan M, Clark P, Shinnar S, Vinks AA, Mizuno K, Glauser TA; Childhood Absence Epilepsy Study Group.

Neurology. 2016 Apr 26;86(17):1613-21. doi: 10.1212/WNL.0000000000002611. Epub 2016 Mar 30.

3.

Long-term outcomes of generalized tonic-clonic seizures in a childhood absence epilepsy trial.

Shinnar S, Cnaan A, Hu F, Clark P, Dlugos D, Hirtz DG, Masur D, Mizrahi EM, Moshé SL, Glauser TA; Childhood Absence Epilepsy Study Group.

Neurology. 2015 Sep 29;85(13):1108-14. doi: 10.1212/WNL.0000000000001971. Epub 2015 Aug 26.

4.

Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months.

Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Adamson PC; Childhood Absence Epilepsy Study Team.

Epilepsia. 2013 Jan;54(1):141-55. doi: 10.1111/epi.12028. Epub 2012 Nov 21.

5.

Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy.

Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Capparelli EV, Adamson PC; Childhood Absence Epilepsy Study Group.

N Engl J Med. 2010 Mar 4;362(9):790-9. doi: 10.1056/NEJMoa0902014.

Supplemental Content

Loading ...
Support Center